GlassScriptPhysician profile
Bipin Bista
NPI 1588849921
$872.57
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $47.87 · 2021: $190 · 2022: $174 · 2023: $249 · 2024: $71.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $321.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $137.38 | 2021-2023 | |
| Horizon Therapeutics Plc | $132.19 | 2022-2023 | Krystexxa |
| Travere Therapeutics, INC. | $131.24 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $91.52 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $57.60 | 2020-2021 | |
| Vifor Pharma, INC. | $52.27 | 2023 | Veltassa |
| Takeda Pharmaceuticals U.S.A., INC. | $46.44 | 2024 | Livtencity |
| Otsuka America Pharmaceutical, INC. | $37.48 | 2019-2022 | |
| Veloxis Pharmaceuticals, INC. | $27.82 | 2019 | |
| Abbott Laboratories | $26.41 | 2021 | |
| Mallinckrodt Enterprises LLC | $24.97 | 2019 | |
| Fresenius USA Marketing, INC. | $20.35 | 2022 | |
| Amgen INC. | $20.30 | 2022 | |
| Merck Sharp & Dohme LLC | $17.61 | 2023 | Prevymis |
| Genzyme Corporation | $17.53 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $17.28 | 2019 | |
| Glaxosmithkline, LLC. | $14.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bipin Bista listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.